Clinical Trials
55 trialsTAURUS
European Myeloma Network B.V.
BORTEM-17
Haukeland University Hospital
A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM
Peking University First Hospital
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML
Zhongnan Hospital
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
Singapore General Hospital
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
Sun Yat-sen University
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Wuerzburg University Hospital
PVd Versus Vd in NDMM Patients With RI
RenJi Hospital
KMM1910
Samsung Medical Center
Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis
Peking Union Medical College Hospital
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Hellenic Society of Hematology
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
Hospital General de Mexico
Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis
Guangdong Provincial People's Hospital
Borma
Samsung Medical Center
ALL-MB 2015
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients
Seoul National University Hospital
A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma
Zhejiang Cancer Hospital
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
Leaf Vertical Inc.
Myeloma XI
University of Leeds
Modified Bortezomib-based Combination Therapy for Multiple Myeloma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
CyBorD-Dara
National University of Ireland, Galway, Ireland
Bortezomib in Intrahepatic Cholangiocellular Carcinoma
Eastern Hepatobiliary Surgery Hospital
A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL
Ruijin Hospital
BOMB-THROW
Seoul National University Hospital
Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.
Jinling Hospital, China
Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)
Milton S. Hershey Medical Center
Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)
University of Southern California
(R-HAD)
European Mantle Cell Lymphoma Network
The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma
Fujian Medical University
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Threshold Pharmaceuticals
CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma
Sun Yat-sen University
Phase-0-MM
Aalborg University Hospital
MUKsix
University of Leeds
Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy
Sun Yat-sen University
Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
National Cancer Institute (NCI)
Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
National Cancer Institute (NCI)
Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma
Second Affiliated Hospital of Soochow University
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
PIAPL
Christian Medical College, Vellore, India
VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
Columbia University
KMM-97
Chonnam National University Hospital
Bortezomib
Clinical Service, China
A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma
Peter MacCallum Cancer Centre, Australia
Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
Second Military Medical University
Bortezomib and High-dose Melphalan at Myeloma Relapse
Nordic Myeloma Study Group
Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC
Aptium Oncology Research Network
HEMOS AML 0106
University of Bologna